4 min read

Tasso and UBC Partner to Advance Post-Approval Research

UBC’s late-stage expertise and Tasso’s cutting-edge integrated blood sample collection solution partner.
UBC's late-stage expertise and Tasso's cutting-edge integrated blood sample collection solution partner.

Seattle and Blue Bell, P.A., June 27, 2023 – Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, and United BioSource LLC (UBC), a leading provider of evidence development solutions for the biopharmaceutical industry, today announced a partnership to provide more efficient, streamlined, and convenient sample collection and analysis options for post-approval research to improve study design and enable a better patient experience.

The new partnership will bring together Tasso’s devices for at-home, virtually painless clinical-grade blood sample collection and end-to-end collection and analysis solutions with UBC’s late-stage research expertise in evidence development and participant support services, including digital recruitment and engagement strategies, powerful real-world data infrastructure and rapid analytics software. Together, the two companies will offer a complete solution for biopharmaceutical companies seeking to improve participant retention and compliance, boost patient engagement, and enroll more diverse patient populations in decentralized post-approval studies.

Tasso and UBC have recently been awarded a late-stage biomarker monitoring study, with additional projects expected to follow.

“This collaboration combines UBC’s expertise in modernized study design and execution with our innovative offerings to create an unprecedented new solution for patient-centric, decentralized research,” said Ben Casavant, PhD, CEO and co-founder of Tasso, Inc. “Importantly, the collaboration will not only provide sponsors with the high-quality data they require but will also drive much-needed improvement in the patient experience and trial participant diversity.”

Research utilizing the joint offering will be powered by Tasso’s integrated solutions to streamline blood sample collection and analysis. After sponsors provide a list of samples needed, Tasso will handle shipping at-home blood collection kits directly to research participants, manage transport of samples to an analytical laboratory that has validated the specific test(s) needed, and communicate lab results back to the sponsor. The fully integrated Tasso Connect portal will ensure samples can be tracked with out-of-the-box functionality, and for seamless connectivity, partners can link with their own systems through Tasso’s API integration.

“With today’s rapidly evolving post-approval drug development requirements, there’s a real need to help sponsors efficiently, effectively, and safely execute and manage late-stage and real-world evidence generation research programs that meet regulatory and payer requirements and support their product commercialization objectives,” said Aaron Berger, Head of Evidence Development, UBC. “Our partnership with Tasso allows us to collectively provide flexible, integrated, and innovative offerings that improve the patient experience and advance decentralized research methods.”

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Media Contact:

Dina Schneider

Tasso, Inc.

(206) 822-4186 x1016


About UBC

United BioSource LLC (UBC) is the leading provider of evidence development solutions with an expertise in unifying evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. Underpinned by our scientific expertise, data and analytics, and innovative technologies, we offer our customers flexible solutions generating the relevant real-world data necessary to make more informed decisions earlier, meet stakeholder requirements, and, ultimately, drive better patient outcomes. For additional information, visit https://ubc.com/.

Media Contact:

Amber Frasketi


(215) 588-8423


Other Recent Posts

5 min read

UBC and Thread Expand SitePlus Offering and Active Studies with BioPharma Sponsors to Optimize Evidence Generation

This augments the central site model with additional research services and tech to widen recruitment and improves site and patient experience.
3 min read

UBC Appoints Anthony Luttenberger Chief Commercial Officer

Biopharma services industry veteran brings decades of experience spanning late-stage, clinical trials, & post-approval commercial support.
1 min read

UBC Listed as a Citeline Awards Finalist for Excellence in RWE

UBC is once again a finalist for the Citeline Awards, with our 2024 nomination coming in the Excellence in RWE category.

Thank You for Connecting with UBC

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

What You Can Expect Next

Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.

Get Ready to Change Your Business

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

Service Request

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.